A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, parallel group study will investigate the
safety and tolerability, and the effect of aleglitazar in combination with aspirin on renal
function, renin-angiotensin system and platelet aggregation in healthy volunteers. Volunteers
will be randomized to receive daily doses of aleglitazar or placebo in combination with
aspirin. The anticipated time on study drug is 5 weeks.